LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ)

Every figure this model derived for LGNXZ, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 278,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 1,357,758,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,457,116,000 AssetsCurrent 2026-06-30
current liabilities 46,736,000 LiabilitiesCurrent 2026-06-30
equity 967,516,000 StockholdersEquity 2026-06-30
interest expense 6,190,000 InterestExpenseNonoperating 2026-06-30
ocf 131,714,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 290,542,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 53,265,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up LGNXZ on one particular measure came for.

RatioValue
cash operating margin62.27
current ratio31.6
current ratio reported31.18
deferred revenue growth459.46
dilution pct10.96
ebit cagr167.51
fcf margin45.24
growth cv2.19
interest cover15.3
operating margin32.61
owner earnings margin26.91
revenue growth54.89
revenue growth per share39.58
roic10.16
rule of 4087.49
sbc pct revenue18.33

What to be careful about

What this model itself distrusts about LGNXZ's figures. Written by the derivation as it ran, not added afterwards.